

## DAFTAR PUSTAKA

- Abbas, A.K., A.H. Lichtman, S. Pillai, 2012, *Cellular and Molecular Immunology 7th Ed.*, Elsevier.
- Albert, M.L., S.F. Pearce, L.M. Francisco, B. Sauter, P. Roy, R.L. Silverstein, et al., 1998, *Immature Dendritic Cells Phagocytose Apoptotic Cells via Alpha-Beta5 and CD36, and Cross-Present Antigens to Cytotoxic T Lymphocytes*. *J Exp Med*, **188**:1359-1368.
- Alphar, H.O, I. Papanicolaou, V.W Bramwell. 2005, *Strategies for DNA Vaccine Delivery, Expert Opin. Drug Deliv*, **2 (5)**:829-842.
- Amorij, JP., W.L.J. Hinrichs, H.W. Frijlink, J.C. Wilschut, A. Hucriede, 2010, *Needle-Free Influenza Vaccination*. *Lancet Infect Dis*, **10**, 699–711.
- Anderson, DP. and Swicki, AK. 1995, *Basic Hematology and Serology for Fish Health Programs*. Paper presented in second symposium on diseases in Asians Aquaculture “*Aquatic Animal Health and The Environment*”, Phuket, Thailand.
- Ansel. And Howard, C. 1989, *Pengantar Bentuk Sediaan Farmasi*. UI Press, Jakarta.
- Atherton M.J., Morris J.S., McDermott M.R., Lichty B.D. 2016, *Cancer Immunology and Canine Malignant Melanoma: A comparative review*. *Vet. Immunol. Immunop*, **169**:15–26.
- Baulny MOD, Quentel C, Fournier V, Lamour F, Gouvello RL. 1996. *Effect of Long Term Oral Administration of B Glucan as an Immunostimulant or an Adjuvant on Some Non-Specific Parameters of The Immune Response of Turbot Scophthalmus Macimus*. *Dis Aquat Org*.
- Chattergoon, M.A., T.M. Robinson., J.D. Boyer., D.B. Weiner. 1998, *Specific Immune Induction Following DNA-based Immunization through In Vivo Transfection and Activation of Macrophages/Antigen-Presenting Cells*. *J Immunol*, **160**:5707–5718.
- Condon, C., S.C. Watkins, C.M., Celluzzi, K., Thompson, L.D., Falo, Jr. 1996, *DNA-Based Immunization by In Vivo Transfection of Dendritic Cells*, *Nat Med*, **2**:1122–1128.

- Departemen Kesehatan Republik Indonesia. 1995, Farmakope Indonesia Edisi IV, Jakarta:Departemen Kesehatan Republik Indonesia, 173-174;519-521;1044.
- Flingai, S., M. Czerwonko, J. Goodman, S.B. Kudchodkar, K Muthumani, dan D.B. Weiner, 2013, *Synthetic DNA Vaccines: Improved Vaccine Potency by Electroporation and CoDelivered Genetic Adjuvants*, *Frontiers Immunol.*, **4(354)**:1-10.
- Gargett, T., B. Grubor-Bauk, D. Miller, T. Garrod, S. Yu, S. Wesselingh, A. Suhrbier, dan E.J. Gowans, 2014, *Increase in DNA Vaccine Efficacy by Virosome Delivery and Co-expression of A Cytolytic Protein*. *Clin. Translation. Immunol.*, **18**:1-7.
- Garrido, F., Aptsiauri, N., Doorduijn, E.M., Garcia Lora, A.M., Van Hall. 2016, T. *The Urgent Need to Recover MHC class I in Cancers for Effective Immunotherapy*. *Curr. Opin. Immunol.* **39**:44–51.
- Guidelines for assuring the quality of DNA vaccines. In: *WHO Expert Committee on Biological Standardization*. Forty-seventh report. Geneva, World Health Organization, 1998, Annex 3 (WHO Technical Report Series, No. 878).
- Guidelines on nonclinical evaluation of vaccines. In: *WHO Expert Committee on Biological Standardization*. Fifty-fourth Report. Geneva, World Health Organization, 2005, Annex 1 (WHO Technical Report Series, No. 927).
- Guidelines on clinical evaluation of vaccines: regulatory expectations. In: *WHO Expert Committee on Biological Standardization*. Fifty-second report. Geneva, World Health Organization, 2004, Annex 1 (WHO Technical Report Series, No. 924).
- Good manufacturing practices for pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations*. Thirty-seventh report. Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series, No. 908).
- Good manufacturing practices for biological products. In: *WHO Expert Committee on Biological Standardization*. Forty-second report. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 822).

- Haidari, G., Cope, A., Miller, A., Venables, S., Yan, C., Ridgers H., Reijonen, K., Hannaman, D., Spentzou, A., Hayes, P., et al. 2017, *Combined Skin and Muscle Vaccination Differentially Impact The Quality of Effector T Cell Functions: The CUTHIVAC-001 Randomized Trial*. *Sci*, **7**:13011.
- Hendriksen, C. 1998, *Validation of Alternative Methods for the Potency Testing of Vaccines*. *ATLA*. **26**:747-61.
- Jiao S., Williams P., Berg R.K., Hodgeman B.A., Liu L., Repetto G., Wolff J.A. 1992, *Direct Gene Transfer Into Nonhuman Primate Myofibers In Vivo*. *Hum. Gene Ther.* **3**:21–33.
- Kripalni, A. 2016, *Histotological Aspect of Vaccine*. *Int J of Gyanecol and Obst.* **2**:1-1. 2.
- Kutzler, W.A. dan D.B. Weiner. 2008, *DNA Vaccines: Ready for Prime Time?*, *Genetics*, **9**:776-788.
- Lazzaro, S., Giovani, C., Mangiavacchi, S., Magini, D., Maione, D., Baudner, B., Geall, A.J., De Gregorio, E., D’Oro, U., Buonsanti, C. 2015, *CD8 T-cell Priming Upon mRNA Vaccination is Restricted to Bone-marrow-derived Antigen-presenting Cells and may Involve Antigen Transfer from Myocytes*. *Immunology*. **146**:312–326.
- Maecker, H.T., Umetsu, D.T., DeKruyff, R.H., Levy, S. 1998, *Cytotoxic T cell Responses to DNA Vaccination: Dependence on Antigen Presentation Via Class II MHC*. *J. Immunol.* **161**:6532–6536.
- Mairhofer, J. and Lara, A.R. 2014, *Advances in Host and Vector Development for The Production of Plasmid DNA Vaccines*. *Methods Mol. Biol.* **1139**:505–541.
- Manam, S., Ledwith, B.J., Barnum, A.B., Troilo, P.J., Pauley, C.J., Harper, L.B., Griffiths, T.G., 2nd, Niu, Z., Denisova, L., Follmer, T.T., et al. 2004, *Plasmid DNA Vaccines: Tissue Distribution and Effects of DNA Sequence, Adjuvants and Delivery Method on Integration Into Host DNA*. *Intervirology*. **43**:273–281.

- Maslow, J.N. 2017, *Vaccines for Emerging Infectious Diseases: Lessons from MERS Coronavirus and Zika Virus*. Hum. Vacc. Immunother. **13**:2918–2930.
- Mincheff, M., Tchakarov, S., Zoubak, S., Loukinov, D., Botev, C., Altankova, I., Georgiev, G., Petrov, S., Meryman, H.T. 2000, *Naked DNA and Adenoviral Immunizations for Immunotherapy of Prostate Cancer: A Phase I/II Clinical Trial*, Eur, Urol. **38**:208–217.
- Ottensmeier, C., Bowers, M., Hamid, D., Maishman, T., Regan S., Wood W., Cazaly A., Stanton L. 2016, *Wilms' Tumour Antigen 1 Immunity via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation: A Phase II Non-Randomised Clinical Trial (WIN)*, NIHR Journals Library, Southampton, UK.
- Saunders., Philadelphia., Akbari, O, N., Panjwani, S., Garcia, R., Tascon, D., Lowrie, B., Stockinger. 1999, *DNA Vaccination: Transfection and Activation of Dendritic Cells as Key Events for Immunity*. J Exp Med., **189**:169–178.
- Shimizu, K., Iyoda, T., Okada, M., Yamasaki, S., Fujii, S.I. 2018, *Immune Suppression and Reversal of The Suppressive Tumor Microenvironment*. Int. Immunol. **30**:445–454.
- Suryo. 2004, *Genetika Strata I*, Universitas Gadjah Mada, Yogyakarta.
- Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., Umansky, V. 2018, *Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors*. Front. Immunol. **9**:1310.
- Weniger, B.G., Anglin, I.E., Tong, T., Pensiero, M., Pullen, J.K. 2015, Workshop Report: Nucleic Acid Delivery Devices for HIV Vaccines: *Workshop proceedings, National Institute of Allergy and Infectious Diseases*. Bethesda, Maryland, USA. **36**:427–437.
- Wischhusen, J., Waschbisch, A., Wiendl, H. 2007, *Immune-refractory Cancers and Their Little Helpers--an Extended Role for Immunetolerogenic MHC Molecules HLA-G and HLA-E?* Semin. Cancer Biol. **17**:459–468.

Yuwono, T., 2008, Biologi Molekuler. Erlangga, Jakarta